NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD
172.06
+4.59 (+2.74%)
The current stock price of ASND is 172.06 USD. In the past month the price increased by 14.64%. In the past year, price increased by 25.41%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900 DK
CEO: Jan Moller Mikkelsen
Employees: 1017
Phone: 4570222244
The current stock price of ASND is 172.06 USD. The price increased by 2.74% in the last trading session.
The exchange symbol of ASCENDIS PHARMA A/S - ADR is ASND and it is listed on the Nasdaq exchange.
ASND stock is listed on the Nasdaq exchange.
23 analysts have analysed ASND and the average price target is 211.65 USD. This implies a price increase of 23.01% is expected in the next year compared to the current price of 172.06. Check the ASCENDIS PHARMA A/S - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ASCENDIS PHARMA A/S - ADR (ASND) has a market capitalization of 10.35B USD. This makes ASND a Large Cap stock.
ASCENDIS PHARMA A/S - ADR (ASND) currently has 1017 employees.
ASCENDIS PHARMA A/S - ADR (ASND) has a support level at 158.13 and a resistance level at 172.07. Check the full technical report for a detailed analysis of ASND support and resistance levels.
The Revenue of ASCENDIS PHARMA A/S - ADR (ASND) is expected to grow by 86.27% in the next year. Check the estimates tab for more information on the ASND EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ASND does not pay a dividend.
ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2025-09-01, after the market close.
ASCENDIS PHARMA A/S - ADR (ASND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.51).
The outstanding short interest for ASCENDIS PHARMA A/S - ADR (ASND) is 6.95% of its float. Check the ownership tab for more information on the ASND short interest.
ChartMill assigns a technical rating of 9 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 93.5% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ASND. ASND may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -6.51. The EPS increased by 35.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -32.05% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ASND. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of 44.29% and a revenue growth 86.27% for ASND